Analysis of Information on Drug Adverse Reactions Using US Food and Drug Administration Adverse Event Reporting System (FAERS)

被引:1
|
作者
Nango, Daisuke [1 ]
Sekizuka, Tuyoshi [1 ]
Goto, Makoto [2 ]
Echizen, Hirotoshi [3 ]
机构
[1] Shin Yurigaoka Gen Hosp, Dept Pharm, Asao Ku, 255 Furusawa Tsuko, Kawasaki, Kanagawa 2150026, Japan
[2] INTAGE Healthcare Inc, Chuo Ku, 3-5-7 Kawara Machi, Osaka 5410048, Japan
[3] Meiji Pharmaceut Univ, 2-522-1 Noshio, Kiyose, Tokyo 2048588, Japan
关键词
medical big data; adverse event; signal detection; U. S. Food and Drug Administration Adverse Event Reporting System (FAERS); ACUTE-PANCREATITIS;
D O I
10.1248/yakushi.21-00178-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nowadays, medical big data has been developed and made available in a variety of fields such as epidemiology and pharmacovigilance. Spontaneous reporting databases are one category of medical big data and that has been adequate for analysing events related to side effects that rarely occur in general practice. These data are freely available in several countries. In Japan, the Pharmaceuticals and Medical Devices Agency has developed the Japanese Adverse Drug Event Report (JADER), and the Food and Drug Administration (FDA) developed the FDA Adverse Events Reporting System (FAERS) in the United States. Since the release of these medical big data, many researchers in academic and research setting have accessed them, but it is still difficult for many medical professionals to analyse these data due to costs and operation of requisite statistical software. In this section, we give some tips to study spontaneous reporting databases resulting from our learning experiences.
引用
收藏
页码:341 / 344
页数:4
相关论文
共 50 条
  • [1] US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS)
    Thomas J. Moore
    Richard L. Morrow
    Colin R. Dormuth
    Barbara Mintzes
    [J]. Pharmaceutical Medicine, 2020, 34 : 135 - 140
  • [2] US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS)
    Moore, Thomas J.
    Morrow, Richard L.
    Dormuth, Colin R.
    Mintzes, Barbara
    [J]. PHARMACEUTICAL MEDICINE, 2020, 34 (02) : 135 - 140
  • [3] Comparisons of adverse event reporting for colistin versus polymyxin B using the US Food and Drug Administration Adverse Event Reporting System (FAERS)
    Cong Bang Truong
    Durham, Spencer H.
    Qian, Jingjing
    [J]. EXPERT OPINION ON DRUG SAFETY, 2021, 20 (05) : 603 - 609
  • [4] Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the US Food and Drug Administration Adverse Event Reporting System (FAERS)
    Rahman, Md. Motiur
    Alatawi, Yasser
    Cheng, Ning
    Qian, Jingjing
    Plotkina, Annya V.
    Peissig, Peggy L.
    Berg, Richard L.
    Page, David
    Hansen, Richard A.
    [J]. EPILEPSY RESEARCH, 2017, 135 : 71 - 78
  • [5] Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database
    Subeesh, Viswam
    Maheswari, Eswaran
    Singh, Hemendra
    Beulah, Thomas Elsa
    Swaroop, Ann Mary
    [J]. CURRENT DRUG SAFETY, 2019, 14 (01) : 21 - 26
  • [6] Empirical estimation of under-reporting in the US Food and Drug Administration Adverse Event Reporting System (FAERS)
    Alatawi, Yasser M.
    Hansen, Richard A.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2017, 16 (07) : 761 - 767
  • [7] Cardiovascular safety profile of romosozumab: A pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system (FAERS)
    Kvist, Annika
    Faruque, Junaid A. Y.
    Burden, Andrea M.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 159 - 160
  • [8] Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)
    Kvist, Annika Vestergaard
    Faruque, Junaid
    Vallejo-Yague, Enriqueta
    Weiler, Stefan
    Winter, Elizabeth M.
    Burden, Andrea M.
    [J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (08)
  • [9] Stimulated Reporting: The Impact of US Food and Drug Administration-Issued Alerts on the Adverse Event Reporting System (FAERS)
    Hoffman, Keith B.
    Demakas, Andrea R.
    Dimbil, Mo
    Tatonetti, Nicholas P.
    Erdman, Colin B.
    [J]. DRUG SAFETY, 2014, 37 (11) : 971 - 980
  • [10] Stimulated Reporting: The Impact of US Food and Drug Administration-Issued Alerts on the Adverse Event Reporting System (FAERS)
    Keith B. Hoffman
    Andrea R. Demakas
    Mo Dimbil
    Nicholas P. Tatonetti
    Colin B. Erdman
    [J]. Drug Safety, 2014, 37 : 971 - 980